Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
复制标题
DOI：
10.1371/journal.pone.0182117
复制
发表时间：
2017
期刊：
影响因子：
3.7
通讯作者：
Kong JL
中科院分区：
文献类型：
--
作者：
Tang ZM;Ling ZG;Wang CM;Wu YB;Kong JL
我们进行了一项全面的综述和荟萃分析，以评估血清单一和多重肿瘤相关自身抗体（TAAb）在肺癌（LC）患者中的诊断价值。我们检索了MEDLINE和EMBASE数据库，以寻找血清TAAb诊断LC的相关研究。主要结果包括检测的敏感性、特异性和准确性。系统综述和荟萃分析包括31篇单一自身抗体和39篇多重自身抗体的文章。酶联免疫吸附试验（ELISA）是最常用的检测方法。对于所有分期和早期LC患者的诊断，不同TAAb的单一或组合显示出不同的诊断价值。虽然单个TAAb显示出较低的诊断灵敏度，但多重自身抗体的组合提供了相对较高的灵敏度。对于LC所有阶段患者中同一组自身抗体的荟萃分析，6种TAAb组的汇总结果（p53、NY-ESO-1、CAGE、GBU 4 -5、膜联蛋白1和SOX 2）是：灵敏度38%（95% CI 0.35-0.40），特异性89%（95% CI 0.86-0.91），诊断准确率65.9%（范围62.5-81.8%），AUC 0.52（0.48-0.57），而7种TAAb的汇总估计值（p53、CAGE、NY-ESO-1、GBU 4 -5、SOX 2、法师A4和Hu-D）是：敏感性47%（95% CI 0.34-0.60），特异性90%（95% CI 0.89-0.92），诊断准确性78.4%（范围67.5-88.8%），AUC 0.90（0.87-0.93）。对于LC早期患者中同一组自身抗体的荟萃分析，7种TAAb和6种TAAb的两组灵敏度分别为40%和29.7%，而特异性分别为91%和87%。血清单一或多重自身抗体组合可作为LC患者各期或早期诊断的工具，但多重自身抗体组合显示出更高的检测能力; 7种TAAb组合的诊断价值高于6种TAAb组合，可作为LC早期检测的潜在生物标志物。
We performed a comprehensive review and meta-analysis to evaluate the diagnostic values of serum single and multiplex tumor-associated autoantibodies (TAAbs) in patients with lung cancer (LC). We searched the MEDLINE and EMBASE databases for relevant studies investigating serum TAAbs for the diagnosis of LC. The primary outcomes included sensitivity, specificity and accuracy of the test. The systematic review and meta-analysis included 31 articles with single autoantibody and 39 with multiplex autoantibodies. Enzyme-linked immunosorbent assay (ELISA) was the most common detection method. For the diagnosis of patients with all stages and early-stage LC, different single or combinations of TAAbs demonstrated different diagnostic values. Although individual TAAbs showed low diagnostic sensitivity, the combination of multiplex autoantibodies offered relatively high sensitivity. For the meta-analysis of a same panel of autoantibodies in patients at all stages of LC, the pooled results of the panel of 6 TAAbs (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2) were: sensitivity 38% (95% CI 0.35–0.40), specificity 89% (95% CI 0.86–0.91), diagnostic accuracy 65.9% (range 62.5–81.8%), AUC 0.52 (0.48–0.57), while the summary estimates of 7 TAAbs (p53, CAGE, NY-ESO-1, GBU4-5, SOX2, MAGE A4 and Hu-D) were: sensitivity 47% (95% CI 0.34–0.60), specificity 90% (95% CI 0.89–0.92), diagnostic accuracy 78.4% (range 67.5–88.8%), AUC 0.90 (0.87–0.93). For the meta-analysis of the same panel of autoantibodies in patients at early-stage of LC, the sensitivities of both panels of 7 TAAbs and 6 TAAbs were 40% and 29.7%, while their specificities were 91% and 87%, respectively. Serum single or combinations of multiplex autoantibodies can be used as a tool for the diagnosis of LC patients at all stages or early-stage, but the combination of multiplex autoantibodies shows a higher detection capacity; the diagnostic value of the panel of 7 TAAbs is higher than the panel of 6 TAAbs, which may be used as potential biomarkers for the early detection of LC.